Immunotherapy based on checkpoint inhibitors has revolutionized the management of the most common advanced tumours, such as lung cancer. These therapies have markedly improved the survival of patients and decreased the rate of relapse of the underlying oncological disease. However, the widespread use of immunotherapy has lead to an exponential rise of immune-related adverse events, whose clinical manifestations, severity and management has been shown to differ to the proposed by the registry studies. Moreover, concerns about the risk of reactivation of infections and its use in special populations such as HIV or solid-organ transplantation have also arisen.
The Goal of this Research Topic is to provide an overview on the management of the main immune-related adverse events (irAEs), based on both registry studies and real-world clinical practice, including the potential harm of therapy for irAEs on the cancer progression. Moreover we aim to highlight special situations in patients with severe immune-related adverse events: possibility of retreatment, use of corticoid-sparing agents, management of life-threatening and concomitant adverse events. Other aims include:
- Overview and recommendations on the screening of infections and other comorbidities prior to the beginning of immunotherapy.
- Overview and management of infections associated with oncological immunotherapy.
- Immunotherapy in special populations: solid-organ transplant, HIV-infected individuals, advanced liver disease, chronic viral hepatitis, chronic kidney disease, underlying autoimmune diseases.
- Checkpoint inhibitors and SARS CoV-2 infection and vaccines.
This Research Topic will focus on the general management of patients about to initiate oncological checkpoint inhibitors and the complications associated with these therapies including but not limited to the follow topics:
- Screening of underlying infections prior to the beginning of immunotherapy.
- Immunotherapy for special populations (solid-organ transplant, HIV-infected individuals, advanced liver disease, viral hepatitis, chronic kidney disease, underlying autoimmune diseases, latent tuberculosis).
- Dealing with immunotherapy complications: immune-related adverse events (irAEs).
- Effect of corticosteroids and biologic therapy on cancer progression.
- Checkpoint inhibitors and SARS CoV-2 infection and vaccines.
Immunotherapy based on checkpoint inhibitors has revolutionized the management of the most common advanced tumours, such as lung cancer. These therapies have markedly improved the survival of patients and decreased the rate of relapse of the underlying oncological disease. However, the widespread use of immunotherapy has lead to an exponential rise of immune-related adverse events, whose clinical manifestations, severity and management has been shown to differ to the proposed by the registry studies. Moreover, concerns about the risk of reactivation of infections and its use in special populations such as HIV or solid-organ transplantation have also arisen.
The Goal of this Research Topic is to provide an overview on the management of the main immune-related adverse events (irAEs), based on both registry studies and real-world clinical practice, including the potential harm of therapy for irAEs on the cancer progression. Moreover we aim to highlight special situations in patients with severe immune-related adverse events: possibility of retreatment, use of corticoid-sparing agents, management of life-threatening and concomitant adverse events. Other aims include:
- Overview and recommendations on the screening of infections and other comorbidities prior to the beginning of immunotherapy.
- Overview and management of infections associated with oncological immunotherapy.
- Immunotherapy in special populations: solid-organ transplant, HIV-infected individuals, advanced liver disease, chronic viral hepatitis, chronic kidney disease, underlying autoimmune diseases.
- Checkpoint inhibitors and SARS CoV-2 infection and vaccines.
This Research Topic will focus on the general management of patients about to initiate oncological checkpoint inhibitors and the complications associated with these therapies including but not limited to the follow topics:
- Screening of underlying infections prior to the beginning of immunotherapy.
- Immunotherapy for special populations (solid-organ transplant, HIV-infected individuals, advanced liver disease, viral hepatitis, chronic kidney disease, underlying autoimmune diseases, latent tuberculosis).
- Dealing with immunotherapy complications: immune-related adverse events (irAEs).
- Effect of corticosteroids and biologic therapy on cancer progression.
- Checkpoint inhibitors and SARS CoV-2 infection and vaccines.
